FDA Grants Upsher-Smith Approval For Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg
2 February 2018 - - US-based pharmaceutical company Upsher-Smith Laboratories, LLC has received US Food and Drug Administration approval of its abbreviated new drug application for Bumetanide Tablets, USP, 0.5 mg, 1 mg, and 2 mg, the company said.
Bumetanide Tablets are a generic version of the brand product, Bumex (bumetanide) Tablets.
Rusty Field, president and CEO of Upsher-Smith, said "We are pleased to begin this year by adding Bumetanide Tablets to our portfolio of quality generic products."
Upsher-Smith Laboratories has strived to deliver quality, affordable generic medications for nearly a century.
In June 2017, Upsher-Smith was acquired by Sawai Pharmaceutical Co., Ltd., a large publicly traded generics company in Japan that had been seeking entry into the US market.